Atrial natriuretic factor (ANF) (1 ttM) markedly These data are compatible with the hypothesis that cGMP is a second messenger for a physiologic action of ANF in the inner medullary collecting duct. ANF apparently activates membrane-bound guanylate cyclase in this segment.
Introduction
Atrial natriuretic factors (ANFs),' peptides released from mammalian cardiac atria, exhibit potent natriuretic, diuretic and smooth muscle relaxant properties (1) (2) (3) (4) . They have been purified and sequenced (5) (6) (7) (8) (9) and have been characterized with regard to their physiological effects in intact animals (1) (2) (3) (4) . Rel- atively little is known, however, about the renal mechanism of ANF action or about the precise target sites for ANF along the nephron. While effects of ANF on glomerular filtration may account for a substantial part of their natriuretic response (5, 10) , effects on renal tubular NaCl and water transport may also play an important role in the overall renal response (1 1, 12) .
The actions of many hormones are mediated by cyclic nucleotides. Earlier studies have shown that ANF increases urinary excretion of cGMP in the dog (13) and increases cGMP accu-mulation in tubule suspensions from dogs (14) , in rat glomeruli (15, 16), and in cultured rat renal papillary tissue (17, 18) . These and other studies in vascular smooth muscle (19, 20) raise the possibility that cGMP may be a second messenger in ANF action. Therefore, in the present study, we used microdissected nephron segments to define precisely those segments of the rat nephron in which ANF increases cGMP content.
In addition, some of the actions of ANF could be due to effects on intracellular cAMP levels. Consequently, we have also examined effects of ANF on peptide hormone-induced changes in the cAMP content of microdissected nephron segments.
Methods
Materials. Synthetic atrial natriuretic factors (ANF , ANF and ANF [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ) and synthetic bovine parathyroid hormone (PTH) (I -34) were purchased from Peninsula Laboratories (Belmont, CA). Except where specifically noted, the 28-amino acid peptide ANF (6-33) (also called Ser-Leu-Arg-Arg-atriopeptin-III or cardionatrin I) was used in all experiments. This has been identified as the chief circulating form of ANF in the rat (9) . Prostaglandin E2 (PGE2) was obtained from PL Biochemicals (Piscataway, NJ). 3-isobutyl-1-methylxanthine (IBMX), arginine vasopressin (AVP), (-)epinephrine (+)bitartrate, DL-propranolol hydrochloride, sodium nitroprusside, L-glutamine, L-alanine and collagenase (type 1) were obtained from Sigma Chemical Co. (St. Louis, MO).
Bovine serum albumin (BSA) was obtained from Armour Pharmaceuticals (Kankakee, IL).
Preparation oftubule suspensions. Preliminary experiments were done in tubule suspensions from rabbits and rats. Male and female rabbits (New Zealand White, 1-3 kg, Small Animal Breeding Facility, National Institutes of Health [NIH] ) were injected with pentobarbital (40 mg/kg body wt i.v.). Furosemide (10 mg) was injected intravenously 15 min before injection of pentobarbital to eliminate medullary osmolality gradients. The kidneys were separately perfused via renal arteries with 10 ml of ice-cold physiological saline (solution 1), which contained (in mM): NaCl, 117; KCI, 5.0; NaHCO3, 25; NaH2PO4, 1.0; MgS04, 1.2; CaCI2, 2.0; glucose, 5.5; L-alanine, 6 .0; and BSA, 1 mg/ml; and was equilibrated with 95% 02-5% CO2. The kidneys were then perfused with -15 ml of ice-cold solution 1 containing collagenase (type 1), 1 mg/ml. Inner medulla or outer medulla were carefully dissected, minced, and incubated in solution I containing collagenase at 37°C for 1 h (for inner medullary tubule suspensions) or 45 min (for outer medullary tubule suspensions). Suspensions were then taken up into and expelled from a 5-ml pipette five times and filtered through three layers of gauze. The suspensions were centrifuged (200-400 g for 3-4 min). The pellets were washed four or five times by resuspending and centrifuging the pellets in solution 2. Solution 2 contained (in mM): NaCl, 135; KCI, 5.0; NaH2PO4, 1.0; MgSO4, 1.2; CaC12, 2.0; glucose, 5.5; L-alanine, 6.0; N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes), 10 Fig. 2 A) or the length of IMCD segments incubated without and with ANF ( Fig. 2 B) . To some tissue
Atrial Natriuretic Factor Effects in Microdissected Nephron 501 time course of the effect of ANF on cGMP accumulation in inner medullary tubule suspensions from rabbits and rats is shown in Fig. 3 A. In the presence of 1 gM ANF and 0.5 mM IBMX, maximal accumulation was obtained within 3 min in suspensions from rabbits or 1 min in suspensions from rats. Based on these results, in subsequent studies, tubule suspensions and nephron segments were incubated with agents for 3 min before measurement of cGMP content. Fig. 3 B shows the relationship between ANF concentration and cGMP accumulation in inner medullary tubule suspensions. ANF (1 uM) increased cGMP content sevenfold in inner medullary tubule suspensions from rabbits and fourfold in suspensions from rats (Fig. 3 B) . The threshold concentration for an increase in cGMP was between 1 and 10 nM in both rabbits and -rats. Sodium nitroprusside (1 mM) also increased cGMP content ofinner medullary tubule suspensions from rabbits and rats ( Fig. 3 A and B) , but had no effect on cAMP content (data not shown).
To test the requirement for IBMX, tubule suspensions from rabbit inner medulla were incubated in the absence of IBMX.
1 gM ANF increased cGMP content fivefold (from 1.4±0.2 fmol/ ,gg protein (n = 6) to 7.3±1.0 fmol/,ug protein (n = 6)). The mean ANF-stimulated cGMP content was 20% of that in the presence of IBMX (compare Fig. 3 B) . Thus, we used IBMX in all subsequent studies except where specifically indicated. Two forms of ANF, ANF (6-33) and ANF , produced virtually identical effects on cGMP accumulation in inner medullary tubule suspensions from rabbits and rats (data not shown). The 16-amino acid fragment ANF (13-28) had no effect. For all remaining studies in this report, we used ANF .
In tubule suspensions from rabbit outer medulla, 1 uM ANF increased cGMP content fivefold (from 0.62±0.05 (n = 3) to 2.94±0.53 (n = 3) fmol/,ug protein) and the threshold for a response was between 1 and 10 nM. The response was -14-fold lower in outer medullary tubule suspensions (2.94 fmol/,gg protein) than in rabbit inner medullary tubule suspensions (41.3 fmol/lg protein).
ANF did not affect cAMP content in tubule suspensions from the inner medulla of rabbits or rats or from the outer medulla of rabbits (data not shown).
cGMP accumulation in microdissected glomeruli and nephron segmentsfrom rats. Incubation of microdissected glomeruli for 3 min with 1 MM ANF increased cGMP accumulation 35-fold (from a control level of 0.48±0.02 (n = 7) to 16.6±2.2 (n = 8) fmol/glomerulus). The minimal concentration of ANF ("threshold dose") required to produce a measurable increase in cGMP accumulation was between 10 nM and 100 nM (Fig.  4) . Sodium nitroprusside (1 mM) increased cGMP content of microdissected glomeruli 13-fold (from a control level of 0.46±0.10 (n = 6) to 5.83±0.32 (n = 12) fmol/glomerulus).
The effects of 1 uM ANF on cGMP accumulation in microdissected collecting duct segments are shown in Fig. 5 . ANF increased cGMP in inner medullary collecting ducts (IMCD) 20-fold (from a control level of 0.07±0.02 [n = 8] to 1.50±0.14 [n = 7] fmol/mm), and slightly increased cGMP accumulation in CCD. There was no significant effect of ANF in OMCD. Incubation of IMCD with 10 nM ANF increased cGMP content 13-fold, about half that produced by 1 MM ANF (Fig. 6 ). 1 nM ANF also increased cGMP content three-to fivefold (Fig. 6) . Sodium nitroprusside (i mM) did not significantly increase cGMP content of IMCD and produced very small increments (~0.1 fmol/mm) in CCD and CAL (data not shown). (Fig. 9 ) (In the presence of 10 nM AVP, PGE2 inhibited the stimulation by 82%).
Since PTH is known to stimulate adenylate cyclase in the proximal tubule, the effects of ANF on PTH-induced increases in cAMP content were studied in microdissected PCT. In four experiments using 6.7 or 67 nM PTH, 1 AM ANF showed no effect on PTH-induced increase ofcAMP content. Similar results 
Discussion
ANF effects on cGMP accumulation in nephron segments. Although little is known regarding the mechanism of action of ANF at the cellular level, cGMP is considered to be a likely intracellular or second messenger of ANF (19, 20) . ANF has been demonstrated to increase membrane-bound, but not soluble, guanylate cyclase activity in broken cell preparations from smooth muscle (20) and kidney (15, 19), and is known to stimulate cGMP accumulation in glomeruli (14-16), tubule suspensions from thick ascending limbs and collecting ducts from dogs (14) , primary cultures of inner medullary collecting ducts (17, 18 ) and renal epithelial cell lines (26) . The chief objective of the present studies was to determine precisely, using microdissected rat nephron segments, those segments of the nephron in which ANF influences cGMP metabolism. Our results show that among renal tubular segments, the inner medullary collecting duct exhibits the largest increase in cGMP content in response to ANF (Figs. 5 and 7) . From the point of view of percentage change from basal cGMP levels, the response in inner medullary collecting ducts was comparable to that seen in glomeruli (compare Fig. 4) . Although small increases in cGMP content were observed in proximal convoluted tubules, proximal straight tubules, thin limbs of Henle's loop, medullary thick ascending limbs of Henle's loop, and cortical collecting ducts, the magnitude of the response in inner medullary collecting ducts was so much greater that we chose to focus our further attention chiefly on this segment. Experiments investigating the relationship between ANF concentration and cGMP accumulation in the IMCD revealed that the threshold ANF concentration for a response was between 0.1 and 1 nM (Fig. 6) . Determinations of ANF levels in circulating blood plasma in rats have disclosed basal ANF concentrations in a similar range (0.02 to 3 nM) (27-30), with higher values following increases in extracellular fluid volume (28, 30) or after vasopressin administration (27). Thus, the dose-response relationship in IMCD is compatible with a physiological action of ANF to increase cGMP in the IMCD. The concentration of ANF required to stimulate cGMP accumulation in microdissected IMCD is not only within the range of reported ambient ANF plasma concentrations, but is also within the reported range of ANF concentrations which produce at least two other presumed physiological effects of ANF, i.e., half-maximal smooth muscle relaxation (< 1 nM ANF) (31) and inhibition of aldosterone secretion (< 2 nM) (32, 33) .
In view ofthe failure ofsodium nitroprusside, a known stimulator of soluble (i.e., cytosolic) guanylate cyclase, to increase cGMP accumulation in microdissected IMCD, we presume that ANF Whereas effects of ANF on renal hemodynamics and glomerular filtration are well documented (1-4), a renal tubular site of action is not yet generally accepted. However, the demonstration in the present study that ANF, at concentrations measured in systemic blood plasma from rats, can increase cGMP production by IMCD adds to the rapidly accruing evidence that ANF may have a physiologic action on the inner medullary collecting duct. Previously, from collecting duct microcatheterization studies, Sonnenberg et al. ( 12) suggested that ANF-induced natriuresis results largely from effects of ANF in the inner medulla associated with decreased NaCl absorption in the IMCD. In addition, Davis et al. (39) reported that ANF greatly attenuates axial solute gradients in inner medulla, consistent with a local site of action in the inner medulla. High affinity ANF binding sites have been demonstrated not only in glomeruli, but also in the inner medulla, probably localized to the IMCD (15, 40, 41). Furthermore, the demonstration by Zeidel et al. (42) that ANF inhibits ouabain-sensitive oxygen consumption in cells isolated from IMCD also points to the IMCD as a likely site of ANF action.
ANF effects on cGMP accumulation in glomeruli. In confirmation of prior studies (14-16), we found that ANF causes a large increase in cGMP accumulation in glomeruli. In contrast to IMCD, glomeruli did not exhibit an increase in cGMP content in response to ANF at concentrations reported in systemic blood plasma in rats. The threshold concentration for an increase in cGMP accumulation by glomeruli was in the range of 10 to 100 nM (Fig. 4) . Despite this observation, we would be reluctant to conclude that ANF does not have a physiological action at the glomerular level for several reasons: (a) Physiological actions of ANF may be mediated by second messengers other than cGMP in glomeruli. (b) Glomeruli are structurally complex with at least four cell types that could in principle respond to ANF (viz. mesangial cells, endothelial cells, visceral epithelial cells, and parietal epithelial cells). Ifthe ANF-responsive cells are embedded within the structure of the glomerulus, higher than physiological ANF concentrations may be required in the incubation medium to allow enough ANF to penetrate to the responsive cell type to elicit a physiological response. (In contrast, normal blood perfusion of the glomerulus would distribute ANF and other circulating peptides throughout the structure of the glomerulus.) (c) Inhibition of AVP-and PTH-induced accumulation of cAMP by PGE2 or C2-adrenergic stimulation in proximal convoluted tubules, medullary thick ascending limbs, and inner medullary collecting ducts indicates that the inhibitory regulatory components of the adenylate cyclase system are functionally present and coupled to the catalytic unit of adenylate cyclase. Consequently, the failure of ANF to inhibit cAMP accumulation in these segments could not be due to the absence ofa normally functioning inhibitory subunit.
a2-Adrenergic effect on hormone-stimulated cAMP accumulation. We have also demonstrated evidence for a2-adrenergic regulation ofAVP responsiveness in IMCD. Incubation ofIMCD with epinephrine plus propranolol (to prevent activation of,Badrenergic receptors) almost completely inhibited AVP-induced accumulation of cAMP. Umemura et al. (24, 44) have also reported a2-adrenergic regulation of cAMP accumulation in isolated proximal convoluted tubules, CCD, OMCD, and glomeruli. Additional studies are needed to characterize more fully, with appropriate analogues and blockers, both the biochemical properties as well as the physiological significance of a2-adrenergic regulation of cAMP accumulation in IMCD.
Conclusion. In summary, our studies of microdissected nephron segments have revealed that, in terms of cGMP production and accumulation, the IMCD is the major renal tubular site of action ofANF. The increase in cGMP accumulation (in percent change) was comparable to that seen in glomeruli and increases in cGMP could be elicited by physiological (i.e., normal circulating) concentrations of ANF. In contrast, ANF had no demonstrable effects on cAMP metabolism in the nephron segments studied. We conclude that the IMCD is a likely site of ANF action on renal tubular NaCl and water transport. Studies using isolated perfused tubules should therefore be useful in determining whether ANF and cGMP have direct regulatory roles in IMCD transport.
